Provides direct equity capital to middle market companies. Offers mezzanine financing solutions for leveraged buyouts and acquisitions. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 74% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
This company is not turning a profit, so the market is pricing its sales instead: 2,784.1× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
The company sells $321K a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 13 buys and 12 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.35 per share each year — regular cash for whoever holds the stock.
A loss of $0 against $321K in annual sales.
The price action doesn’t yet back an upward turn.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.